Bosh sahifaNVON • BMV
add
Novo Nordisk A/S
Yopilish kursi
683,81 $
Kunlik diapazon
676,00 $ - 692,00 $
Yillik diapazon
638,00 $ - 1 624,38 $
Bozor kapitalizatsiyasi
128,86 mlrd USD
Oʻrtacha hajm
10,33 ming
Narx/foyda
-
Dividend daromadliligi
-
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (DKK) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 79,14 mlrd | -7,63% |
Joriy xarajat | 29,73 mlrd | 12,96% |
Sof foyda | 26,89 mlrd | -4,74% |
Sof foyda marjasi | 33,98 | 3,13% |
Har bir ulushga tushum | 6,04 | -4,73% |
EBITDA | 36,66 mlrd | -23,44% |
Amaldagi soliq stavkasi | 21,34% | — |
Balans
Jami aktivlari
Jami passivlari
| (DKK) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 26,96 mlrd | 2,49% |
Jami aktivlari | 542,90 mlrd | 16,60% |
Jami passivlari | 348,86 mlrd | 8,29% |
Umumiy kapital | 194,05 mlrd | — |
Tarqatilgan aksiyalar | 4,44 mlrd | — |
Narxi/balansdagi bahosi | 15,66 | — |
Aktivlardan daromad | 16,70% | — |
Kapitaldan daromad | 29,56% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (DKK) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 26,89 mlrd | -4,74% |
Operatsiyalardan naqd pul | 7,62 mlrd | -38,06% |
Sarmoyadan naqd pul | -42,81 mlrd | 53,07% |
Moliyadan naqd pul | 29,47 mlrd | -20,00% |
Naqd pulning sof oʻzgarishi | -5,62 mlrd | 86,41% |
Boʻsh pul | -34,95 mlrd | -1 011,09% |
Haqida
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Tashkil etilgan
21-dek, 1923
Sayt
Xodimlar soni
69 150